



Test Report/ Certificate of Analysis


Date of Report May 27, 2026

To: Protixa
9276 Scranton Rd, Suite 500, San Diego, CA 92121

From: AxisPharm, LLC

Certificate ID Number: 27May2026-01

Results reported by: Lab Technician
Ning Yang


Review/Approved by: 
QA Director
Dawei Yue

Sample Received: Date: 05/22/2026
Receiving Condition: Acceptable Other: _____
Storage Condition: Room temperature -20°C -80°C
 Other: _____

Sample Name: Orforglipron 2mg; Brand Name: Protixa;
Lot#: ORF2C0526; MFD: 05/2026; BBD: 05/2028

Method(s): LCMS

Procedure(s):
Results:



AxisPharm, LLC

Results only apply to tested Research Use Only samples within Test Report as received. Not for use in humans or animals. Analytical data apply only to the batch tested and do not indicate suitability for diagnostic or therapeutic use. Any unauthorized alteration, reproduction, or relabeling of this COA renders it invalid.



Test Report/ Certificate of Analysis

| Sample Name | Net Weight Measured | MW (g/mol) | Detected | UV Purity (208nm) (%) |
|------------------|---------------------|------------|------------|-----------------------|
| Orforglipron 2mg | 2.2mg | 882.97 | 883.6[M+H] | 99.0 (combined) |

Salts and sugars that serves as fillers in injectables, capsules, or tablets are not considered as impurities.

Conclusion: The product comes with Orforglipron 2.2mg at purity 99.0%. Orforglipron might have isomerized as it shows on UV as two closely overlaped peaks.

UltraPatent

